These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1226 related articles for article (PubMed ID: 27816492)

  • 1. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
    Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF
    J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
    Sangro B; Gomez-Martin C; de la Mata M; Iñarrairaegui M; Garralda E; Barrera P; Riezu-Boj JI; Larrea E; Alfaro C; Sarobe P; Lasarte JJ; Pérez-Gracia JL; Melero I; Prieto J
    J Hepatol; 2013 Jul; 59(1):81-8. PubMed ID: 23466307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.
    Xie C; Duffy AG; Mabry-Hrones D; Wood B; Levy E; Krishnasamy V; Khan J; Wei JS; Agdashian D; Tyagi M; Gangalapudi V; Fioravanti S; Walker M; Anderson V; Venzon D; Figg WD; Sandhu M; Kleiner DE; Morelli MP; Floudas CS; Brar G; Steinberg SM; Korangy F; Greten TF
    Hepatology; 2019 May; 69(5):2048-2060. PubMed ID: 30578687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
    Agdashian D; ElGindi M; Xie C; Sandhu M; Pratt D; Kleiner DE; Figg WD; Rytlewski JA; Sanders C; Yusko EC; Wood B; Venzon D; Brar G; Duffy AG; Greten TF; Korangy F
    Cancer Immunol Immunother; 2019 Apr; 68(4):599-608. PubMed ID: 30688989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
    Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
    Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
    J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
    Kudo M
    Oncology; 2017; 93 Suppl 1():147-159. PubMed ID: 29258079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
    Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
    Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
    France NL; Blair HA
    Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
    Monge C; Xie C; Myojin Y; Coffman-D'Annibale KL; Hrones D; Brar G; Wang S; Budhu A; Figg WD; Cam M; Finney R; Levy EB; Kleiner DE; Steinberg SM; Wang XW; Redd B; Wood BJ; Greten TF
    Cancer Med; 2024 Feb; 13(3):e6912. PubMed ID: 38205877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma.
    Xiao T; Hu S; Dong S; Cai Q; Gong W; Zhang Y; Long C; Li X
    Int Immunopharmacol; 2024 Jun; 134():112144. PubMed ID: 38733820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
    Vonderheide RH; LoRusso PM; Khalil M; Gartner EM; Khaira D; Soulieres D; Dorazio P; Trosko JA; Rüter J; Mariani GL; Usari T; Domchek SM
    Clin Cancer Res; 2010 Jul; 16(13):3485-94. PubMed ID: 20479064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tremelimumab-associated tumor regression following after initial progression: two case reports.
    Shimomura A; Fujiwara Y; Kondo S; Kodaira M; Iwasa S; Kitano S; Tanabe Y; Tamura K; Yamamoto N
    Immunotherapy; 2016; 8(1):9-15. PubMed ID: 26427600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.
    Iñarrairaegui M; Melero I; Sangro B
    Clin Cancer Res; 2018 Apr; 24(7):1518-1524. PubMed ID: 29138342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M
    Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies.
    Zarlashat Y; Mushtaq H; Pham L; Abbas W; Sato K
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.